论文部分内容阅读
目的 观察司来吉兰添加治疗帕金森病的临床疗效及安全性。方法 采用随机双盲安慰剂对照方法,在复方多巴治疗的基础上添加国产司来吉兰治疗40例帕金森病患者,分为司来吉兰治疗组和安慰剂对照组,疗程8周。采用改良的Webster评分量表评估药物疗效并观察不良反应。结果 司来吉兰治疗组治疗前后自身对照Webster评分有明显改善(P<0.05或P<0.01),安慰剂对照组于治疗后第4,6周差异有显著性意义(P<0.05或p<0.01),司来吉兰组疗效优于安慰剂组(P<0.01);司来吉兰组患者治疗的总有效率为80％,与安慰剂组(40％)比较差异有显著性意义(P<0.01)。司来吉兰组患者药物不良反应轻微。结论 司来吉兰是一种安全有效的抗帕金森病辅助药物。
Objective To observe the clinical efficacy and safety of selegiline in the treatment of Parkinson’s disease. Methods A randomized, double-blind, placebo-controlled study was conducted. Forty patients with Parkinson’s disease were enrolled in the study. The patients were divided into selegiline and placebo groups for 8 weeks. The modified Webster scale was used to assess the efficacy and observe the adverse reactions. Results There was a significant improvement in the Webster score of selegiline before and after treatment (P <0.05 or P <0.01), and there was significant difference between the placebo control group at 4 and 6 weeks after treatment (P <0.05 or p < 0.01). The total effective rate of patients in the selegiline group was 80%, which was significantly higher than that of the placebo group (40%) (P <0.01) P <0.01). Patients in the selegiline group had mild adverse drug reactions. Conclusion Selegiline is a safe and effective anti-Parkinson’s disease adjuvant.